262368-44-5

Basic information

• Product Name: (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester
• Synonyms: (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester
• CAS NO: 262368-44-5
• Molecular Weight: 236.314
• Mol File: 262368-44-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester(262368-44-5)
• EPA Substance Registry System: (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester(262368-44-5)

Safety Data

• Hazardous Substances Data: 262368-44-5(Hazardous Substances Data)

Usage

Description

(R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester, commonly known as rufinamide, is a chemical compound with the molecular formula C10H19N3O2. It is a derivative of carbamic acid and is characterized by its anti-epileptic properties. Rufinamide is used to treat seizures, particularly those associated with Lennox-Gastaut syndrome, by inhibiting sodium channels in the brain and stabilizing electrical activity.

Uses

Used in Pharmaceutical Industry:
Rufinamide is used as an anti-epileptic drug for the treatment of seizures, specifically those related to Lennox-Gastaut syndrome. It functions by targeting and inhibiting sodium channels in the brain, which helps to stabilize electrical activity and reduce the frequency of seizures. This application is due to its ability to modulate the electrical activity in the brain, providing a therapeutic effect for patients suffering from this neurological condition.
Additionally, rufinamide is often prescribed in combination with other medications to maximize its effectiveness in managing epilepsy. This combination therapy approach is used to enhance the overall treatment strategy and improve the quality of life for patients with epilepsy.

Upstream product

• 57233-86-0 d-(+)-α-methyl-4-nitrobenzylamine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 694529-38-9 (R)-[1-(4-nitrophenyl)ethyl]carbamic acid t-butyl ester 

Downstream Products

• 1073160-20-9 (R)-tert-butyl 1-(4-(4-chloro-5-(trifluoromethyl)pyrimidin-2-ylamino)phenyl)ethylcarbamate 
• 911124-20-4 (R)-[1-(4-amino-3-iodophenyl)ethyl]carbamic acid t-butyl ester 
• 694529-17-4 N-(4-t-butylbenzyl)-N'-[(1R)-1-(4-aminophenyl)ethyl]thiourea 
• 694529-76-5 (S)-4-methanesulfonamido-α-methylbenzylamine 
• 177948-74-2 (R)-N-[4-(1-aminoethyl)phenyl]acetamide 
• 910534-76-8 (R)-[1-(4-methanesulfonylaminophenyl)ethyl]carbamic acid t-butyl ester 
• 65645-32-1 4-((R)-1-Amino-ethyl)-phenylamine 
• 694529-72-1 [1-(4-acetylamino-phenyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists

A series of chain-branched 1,3-dibenzylthiourea derivatives were synthesized, and tested their antagonist activity against vanilloid receptor 1. Chain-branching led to a significant change in the mode of action and the potency. (R)-Methyl or ethyl-branched 1,3-dibenzylthiourea derivatives showed the most potent antagonist activity up to the IC50 value of 0.05 μM which is 10-fold more potent than capsazepine.